Sanofi Consumer Healthcare shares zoom 16% on Q4 earnings; ₹75 final dividend recommended

At around 11:27 am, the stock was trading at ₹4,617.40 per equity share, up by 15.17%.

The scrip has jumped 14% in the past week and 13% over the month. On a year-to-date basis, it has advanced 1%.

While the stock touched a 52-week low of ₹3,975 per unit on February 24, 2026, it hit a year’s peak of ₹5,894.50 on June 30, 2025.

Sanofi Consumer Healthcare India Q4 results

The consumer healthcare company reported a 50.11% year-on-year (YoY) increase in its net profit to ₹66.5 crore for the fourth quarter of CY25, demonstrating sustained growth momentum across key business segments.

In the same period last year, it had logged a profit of ₹44.3 crore, as stated in a regulatory filing dated February 25.

The Mumbai-based firm’s revenue from operations jumped 47.04% YoY to ₹251 crore during the reporting quarter, compared to ₹170.7 crore in the fourth quarter of CY24.

Its domestic sales grew by 23%, supported by the relaunch of recalled products to the market, Sanofi Consumer Healthcare noted.

Furthermore, its export sales surged by 9.3x due to a low base, it added.

For the full year 2025, the firm recorded a revenue of ₹878.4 crore, marking a 21% YoY growth.

Its PAT for CY25 advanced by 33% YoY to ₹240.1 crore, bolstered by disciplined cost management and improved product mix.

Its domestic sales increased by 7% YoY for the calendar year, and export sales soared by 158% YoY.

Final dividend recommended

The board of directors of Sanofi Consumer Healthcare India also recommended a final dividend of ₹75 per equity share with a face value of ₹10 each for FY25, subject to shareholder approval at the ensuing annual general meeting (AGM).

“The company shall inform in due course the record date/book closure for payment of dividend,” it added.

What the management said

Commenting on the earnings, Himanshu Bakshi, Managing Director, Sanofi Consumer Healthcare India Limited, said: “This quarter’s performance emphasizes the strength of our core portfolio and the disciplined execution of our growth agenda. Our domestic business has delivered healthy double-digit growth for two successive quarters, complemented by strong contributions from our export markets.”

He added that as the company continues to invest in its people and its brands, it remains focused on reinforcing its brand fundamentals and driving operational excellence to unlock the next phase of sustainable growth.

“Guided by science and driven by purpose, we remain committed to simplifying self-care, making it more accessible and effective for every consumer,” Bakshi stated.

Amit Jain, Chairman of Sanofi Consumer Healthcare India, said that the full-year performance reflected the strength of its strategy and the disciplined execution by its teams.

“By driving sustained growth, deepening penetration of our portfolio and accelerating digital transformation, we delivered meaningful outcomes for all our stakeholders. Our strong financial performance this year enables us to reward shareholders with a healthy dividendof ₹75 per share,” Jain added.

Sanofi Consumer Healthcare has a total market capitalisation of ₹10,624.95 crore, as of February 26, 2026, according to data on the NSE.